{"changes":[],"country":"US","description":"Zag Bio develops bifunctional antibodies that ferry self-antigens to the thymus to retrain T cells and restore natural immune tolerance instead of suppressing immunity broadly. It targets patients with autoimmune diseases starting with type 1 diabetes via lead program ZAG-101. Acting in the thymus, the only site of central T-cell tolerance, gives the platform a durable mechanism.","domain":"zagbio.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":[],"lat":42.365635,"lng":-71.104002,"location":"Cambridge, MA","name":"Zag Bio","rounds":[{"amountQuarantined":false,"amountUsd":80000000,"currency":"USD","date":"2025-10-28","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"zagbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-14","status":"attributed","url":null},{"fact":"existence","publisher":"zagbio.com","retrievedAt":"2026-05-14","status":"self-reported","url":"https://zagbio.com"},{"fact":"description","publisher":"zagbio.com","retrievedAt":"2026-05-14","status":"self-reported","url":"https://zagbio.com"}],"stage":"series-a","techStack":["Cloudflare","WordPress","Yoast SEO 26.6","Google Analytics","Google Hosted Libraries","Google Tag Manager","Slick","jQuery Migrate 3.4.1","DoubleClick Floodlight","cdnjs","Cloudflare Bot Management","Vercel Speed Insights"],"totalRaisedUsd":100000000,"updatedAt":"2026-05-14"}